What question did this study set out to answer?

To evaluate the impact of mucosal healing on pregnancy outcomes in patients with ulcerative colitis.

January 23, 2026

P0266Mucosal Healing in Patients with Ulcerative Colitis and Outcomes of Pregnancy

Key Points

To evaluate the impact of mucosal healing on pregnancy outcomes in patients with ulcerative colitis.
Analyzed disease course in 320 ulcerative colitis patients on infliximab, ustekinumab, and vedolizumab.
Mucosal healing assessed using the Mayo score in each treatment group.
Outcomes of pregnancy and birth of healthy children were recorded based on Mayo score.
Infliximab group: 56.5% achieved Mayo score of 0; 32.8% had healthy pregnancies.
Ustekinumab group: 74.5% achieved Mayo score of 0; 19.2% had healthy pregnancies.
Vedolizumab group: 64.9% achieved Mayo score of 0; 23.0% had healthy pregnancies.
Significantly higher pregnancy rates in patients with Mayo score of 0 compared to those with ≥1.

Abstract

Abstract Background A recent meta-analysis showed a significantly lower risk of clinical relapse in patients with UC in endoscopic remission, corresponding to the Mayo score - 0 points, compared to Mayo score - 1 point and more, during follow-up of 12 months or more. Objective: to establish the relationship between the healing of the colon mucosa by the endoscopic Mayo score of the activity of ulcerative colitis (Mayo score) and the onset of pregnancy and the birth of a healthy child in patients with ulcerative colitis. Methods The course of the disease and outcomes were analyzed in 320 patients with UC who received infliximab, ustekinumab, and vedolizumab. The Mucosal Healing was assessed by Mayo score in 108 patients who received infliximab, in 98 patients who received ustekinumab, and in 114 patients who received vedolizumab. Results In the group of patients who received infliximab (n = 108), 61 (56.5%) patients achieved a Mayo score of 0, and 47 (43.5%) patients achieved a Mayo score of ≥ 1. In the group of patients with a Mayo score 0 point -20 (32.8%) patients became pregnant and gave birth to healthy child. Pregnancy and birth of a healthy child in the Mayo ≥1 score group - 2 (4.2%) (OR - 10.976; 95% CI 2.415-49.879; x2 - 10.644; p = 0.002). In the group of patients who received ustekinumab (n = 98), 73 (74.5%) patients achieved a Mayo score of 0, and 25 (25.5%) patients achieved a Mayo score of ≥ 1. In the group of patients with a Mayo score 0 point -14 (19.2%) patients had a pregnancy and delivered a healthy child. Pregnancy and birth of a healthy child in the group Mayo score ≥1 - 1 (4.0%) (OR - 5.695; 95% CI 0.709-45.747; x2 - 4.123; p = 0.043) In the group of patients who received vedolizumab (n = 114), 74 (64.9%) patients achieved a Mayo score of 0, and 40 (35.1%) patients achieved a Mayo score of ≥ 1. In the group of patients with a Mayo score 0 point - 17 (23.0%) patients had a pregnancy and delivered a healthy child. Pregnancy and birth of a healthy child in the group of patients with Mayo score ≥1 - 2 (5.0%) (OR - 11.963; 95% CI 2.549- 56.139; x2 - 4.814; p = 0.029). Conclusion Mucosal Healing in Patients with Ulcerative Colitis (achieving endoscopic remission of Mayo score 0 points) is a favorable factor for pregnancy and birth of a healthy child. Reference: Viscido A, Valvano M, Stefanelli G, Capannolo A, Castellini C, Onori E, Ciccone A, Vernia F, Latella G. Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis. BMC Gastroenterol. 2022 Mar 3;22(1):92. doi: 10.1186/s12876-022-02157-5. PMID: 35240984; PMCID: PMC8895505. Conflict of interest: Prof. Knyazev, Oleg: No conflict of interest Kagramanova, Anna Valeryevna: Lishchinskaia, Albina: No conflict of interest Fadeeva, Nina: No conflict of interest Zviaglova, Mariya: No conflict of interest Gorodetskaya, Anait: No conflict of interest

Perguntar à IA

Bookmark

View Full Paper